Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effect of Immune X on Common Cold Incidence in Healthy Adults (CELFI)

21. august 2026 oppdatert av: Givaudan France Naturals

The Effect of Immune X on the Incidence of the Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial

The goal of this clinical trial is to learn if Immune X can help prevent common cold events in healthy adults who have a history of upper respiratory tract infections. The main questions it aims to answer are:

  • Does Immune X reduce the proportion of participants who experience at least one clinically confirmed common cold event during the study period?
  • Does Immune X affect the number, duration, and severity of common cold events?

Researchers will compare Immune X to a placebo (a look-alike capsule containing inactive ingredients) to see if Immune X helps prevent common cold events.

Participants will:

  • Take Immune X or placebo daily for 16 weeks during the winter season.
  • Attend study visits at the beginning and end of the study and complete questionnaires and symptom assessments throughout the study.
  • Record cold symptoms, medications, and other study information using a smartphone application.
  • Provide blood and stool samples during the study.

Studieoversikt

Status

Har ikke rekruttert ennå

Studietype

Intervensjonell

Registrering (Antatt)

160

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Men and women aged 18 to 65 years.
  • History of at least two upper respiratory tract infections during the previous winter season.
  • Body mass index between 18 and 30 kg/m².
  • Generally healthy, as determined by the investigator.
  • Women of childbearing potential must have a negative pregnancy test and agree to use an effective method of contraception during the study.
  • Covered by French health insurance.
  • Able and willing to provide written informed consent.

Exclusion Criteria:

  • Current or recent upper respiratory tract infection or COVID-19 infection within 2 weeks before enrollment.
  • Acute gastrointestinal infection, including gastroenteritis, within 2 weeks before enrollment.
  • Use of non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks before enrollment.
  • Use of systemic antibiotics within 3 months before enrollment.
  • Receipt of any vaccination within 6 weeks before enrollment.
  • Surgery requiring general anesthesia within 1 month before enrollment.
  • History of chronic respiratory disease, including asthma or chronic obstructive pulmonary disease.
  • Food allergy or chronic/recurrent allergic upper airway conditions requiring regular medical treatment, including moderate to severe allergic rhinitis, hay fever, or chronic rhinosinusitis.
  • Acute lower respiratory tract infection within 6 months before enrollment or ongoing long COVID.
  • Immunodeficiency (including HIV infection) or autoimmune disease, except stable hypothyroidism.
  • Severe or uncontrolled chronic disease, including cancer, significant liver, pancreatic, biliary, or renal disease, inflammatory bowel disease, or cardiovascular disease requiring intensive medical management.
  • Untreated or inadequately controlled diabetes.
  • History or current diagnosis of periodontitis.
  • Current chemotherapy, immunosuppressive therapy, or chronic treatment with corticosteroids or opioids.
  • Specific diets or major dietary changes within 3 months before enrollment, including high-protein, vegan, low-calorie, or low-FODMAP diets, or participation in a weight-loss program.
  • Current use of dietary supplements that may affect immune or gut microbiota parameters, or discontinuation of such supplements less than 6 weeks before enrollment.
  • Current smoking or e-cigarette use, or smoking cessation within 6 months before enrollment.
  • Current drug or alcohol abuse, or a history of abuse within the previous 12 months.
  • Regular consumption of more than 2 alcoholic drinks per day and unwillingness to maintain stable drinking habits during the study.
  • Unwillingness to refrain from using over-the-counter cold remedies, nasal washes or sprays, antihistamines, corticosteroids, or NSAIDs during the study.
  • More than 8 hours per week of vigorous physical activity or planned major changes in physical activity during the study.
  • Any condition or circumstance that, in the investigator's judgment, may place the participant at unacceptable risk or interfere with study participation or interpretation of study results.
  • Current participation in another clinical trial or being in an exclusion period from a previous clinical trial.
  • Pregnant or breastfeeding.
  • Persons deprived of liberty, under legal protection, or unable to provide informed consent.
  • Individuals who have reached the regulatory compensation limit for participation in clinical research.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Immune X
80 participants who meet the eligibility criteria will be randomized to the experimental arm and will receive Immune X for 16 weeks.
500 mg Immune X daily as capsules for 16 weeks.
Placebo komparator: Placebo
80 participants who meet the eligibility criteria will be randomized to the placebo arm and will receive placebo for 16 weeks.
Matching placebo capsules daily for 16 weeks.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Participants With at Least One Clinically Confirmed Cold Event
Tidsramme: Week 2 to Week 16
Proportion of participants with at least one clinically confirmed cold event.
Week 2 to Week 16

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Clinically Confirmed Cold Events
Tidsramme: Week 2 to Week 16
Mean number of clinically confirmed cold events per participant.
Week 2 to Week 16
Duration of Clinically Confirmed Cold Events
Tidsramme: Week 2 to Week 16
Duration of clinically confirmed cold events measured in days.
Week 2 to Week 16
Upper Respiratory Symptoms of Clinically Confirmed Cold Events
Tidsramme: Week 2 to Week 16
Wisconsin Upper Respiratory Symptom Survey (WURSS-24): Zero is equivalent to no symptoms and 7 indicates severe.
Week 2 to Week 16
Cold Symptoms of Clinically Confirmed Cold Events
Tidsramme: Week 2 to Week 16
Jackson Cold Scale: 0 is equivalent to absent symptoms and 3 indicates severe symptoms
Week 2 to Week 16
Illness-Specific Quality of Life During Cold Events
Tidsramme: Week 2 to Week 16
Wisconsin Upper Respiratory Symptom Survey (WURSS-24) quality-of-life score: Zero is equivalent to no interference and 7 indicates severe interference.
Week 2 to Week 16
Time to First Clinically Confirmed Cold Event
Tidsramme: Week 2 to Week 16
Number of days from Day 15 after randomization to the first clinically confirmed cold event.
Week 2 to Week 16
Fatigue
Tidsramme: Baseline, Weeks 4, 8, 12, and 16
Chalder Fatigue Questionnaire (CFQ-11) total score: 0 is equivalent to less/better than usual and 33 indicates much more/much worse than usual.
Baseline, Weeks 4, 8, 12, and 16
Use of Rescue Medication During Cold Events
Tidsramme: Week 2 to Week 16
Number of doses and duration of rescue medication use during cold events.
Week 2 to Week 16
Number of Cold Events (Clinically Confirmed and Unconfirmed)
Tidsramme: Week 2 to Week 16
Mean number of clinically confirmed and unconfirmed cold events per participant.
Week 2 to Week 16
Adverse Events
Tidsramme: Baseline through Week 16
Number of participants with adverse events.
Baseline through Week 16

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Carole Perrin, MD, Cen Experimental

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. september 2026

Primær fullføring (Antatt)

30. april 2027

Studiet fullført (Antatt)

30. april 2027

Datoer for studieregistrering

Først innsendt

17. august 2026

Først innsendt som oppfylte QC-kriteriene

21. august 2026

Først lagt ut (Faktiske)

26. august 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

26. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • C1775
  • 2026-A00903-48 (Annen identifikator: ID-RCB)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere